ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

vapendavir

Also written as “Vapendavir”, “VPV 1000 mg” and “vapendavir 132 mg capsule”.

Its studies are mostly in Enterovirus Infections · Pulmonary Disease, Chronic Obstructive · Asthma · Respiratory Tract Infections, led by 3 companies.

Drug pageVapendavir: every studyAll 10 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Oct 11, 202310 company-led studies, 1 open or runningNext primary completion: Nov 15, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Altesa Biosciencesits history only41 open or runningphase 2since Oct 11, 2023Jun 7, 2023Nov 15, 2027phase 2 · NCT07610395
Vaxart40 open or runningphase 2since Feb 13, 2015Mar 24, 2014none ahead
Biota Scientific Management Ptyits history only20 open or runningphase 2since Aug 3, 2010Aug 3, 2010none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Vaxart only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 24, 2014First study: phase 1 study in HealthyFirst studyNCT02101866 · 36 enrolled · United States
  2. Feb 13, 2015Phase 2 study in AsthmaNCT02367313 · 455 enrolled · United States, Bulgaria, Czechia and more
  3. Aug 15, 2016Phase 1 study in HealthyNCT02877264 · 48 enrolled · United States
  4. Jan 12, 2017Phase 2 study in Respiratory Tract InfectionsNCT03024177

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“VP1 capsid protein inhibitor”ChEMBL 37, by rule

Studies

All 4 Vaxart leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03024177Respiratory Tract Infections2WithdrawnApr 20170
NCT02877264Healthy · United States1CompletedAug 201648
NCT02367313Asthma · United States, Bulgaria, Czechia and more2CompletedDec 2016455
NCT02101866Healthy · United States1CompletedMay 201436

How it is read

Names in the registry

  • “Vapendavir”, 6 entries
  • “VPV 1000 mg”, 1 entry
  • “vapendavir 132 mg capsule”, 1 entry
  • “vapendavir 264 mg tablet”, 1 entry
  • “vapendavir 24 mg/mL oral suspension”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.